VSTMVerastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Verastem (VSTM) Q2 2026 Earnings Call Transcript Revenue surged on CO-PACK launch as cash runway extends into late 2027. | ||
 Verastem Q2 Earnings Call Highlights Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance. The company also reported $15 million | ||
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ... Verastem Inc (VSTM) reports $25.1 million in Q2 net product revenues, secures non-dilutive financing, and progresses its KRAS G12D inhibitor program with promising clinical data. | ||
 Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates Verastem (VSTM) delivered earnings and revenue surprises of +23.91% and +73.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 that could triple. On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ:VSTM). The firm reduced the target price from $15 to $14, which still offers a revised upside potential of over 211%. The price target adjustment accompanies the firm’s […] | IInsider Monkey | |
IInsider Monkey | ||
IInsider Monkey | ||
IInsider Monkey | ||
MMT Newswires | ||